125 related articles for article (PubMed ID: 25076330)
1. Chemotherapy and metformin in pancreatic adenocarcinoma and neuroendocrine tumors.
Burney S; Khawaja KI; Saif MW; Masud F
JOP; 2014 Jul; 15(4):313-6. PubMed ID: 25076330
[TBL] [Abstract][Full Text] [Related]
2. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
3. Update on novel therapies for pancreatic neuroendocrine tumors.
Oberstein PE; Saif MW
JOP; 2012 Jul; 13(4):372-5. PubMed ID: 22797392
[TBL] [Abstract][Full Text] [Related]
4. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Cheng H; Merika E; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):334-8. PubMed ID: 21737890
[TBL] [Abstract][Full Text] [Related]
5. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Pusceddu S; Buzzoni R; Vernieri C; Concas L; Marceglia S; Giacomelli L; Milione M; Leuzzi L; Femia D; Formisano B; Mazzaferro V; de Braud F
Future Oncol; 2016 May; 12(10):1251-60. PubMed ID: 26890290
[TBL] [Abstract][Full Text] [Related]
6. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
[TBL] [Abstract][Full Text] [Related]
7. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in neuroendocrine tumors.
Duque M; Modlin IM; Gupta A; Saif MW
JOP; 2013 Jul; 14(4):372-6. PubMed ID: 23846930
[TBL] [Abstract][Full Text] [Related]
9. Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts.
Lipner MB; Marayati R; Deng Y; Wang X; Raftery L; O'Neil BH; Yeh JJ
PLoS One; 2016; 11(1):e0147113. PubMed ID: 26760500
[TBL] [Abstract][Full Text] [Related]
10. Elderly patients with pancreatic cancer.
Kougioumtzopoulou AS; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):322-5. PubMed ID: 25076333
[TBL] [Abstract][Full Text] [Related]
11. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
12. Anticancer effects of metformin on neuroendocrine tumor cells in vitro.
Vlotides G; Tanyeri A; Spampatti M; Zitzmann K; Chourdakis M; Spttl C; Maurer J; Nölting S; Göke B; Auernhammer CJ
Hormones (Athens); 2014; 13(4):498-508. PubMed ID: 25402373
[TBL] [Abstract][Full Text] [Related]
13. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
14. Interaction of glibenclamide and metformin at the level of translation in pancreatic β cells.
Wang Q; Cai Y; Van de Casteele M; Pipeleers D; Ling Z
J Endocrinol; 2011 Feb; 208(2):161-9. PubMed ID: 21084384
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.
Wolin EM
Cancer Lett; 2013 Jul; 335(1):1-8. PubMed ID: 23419523
[TBL] [Abstract][Full Text] [Related]
16. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment.
Yue W; Yang CS; DiPaola RS; Tan XL
Cancer Prev Res (Phila); 2014 Apr; 7(4):388-97. PubMed ID: 24520038
[TBL] [Abstract][Full Text] [Related]
17. [Metformin--new treatment strategies for gynecologic neoplasms].
Milewicz T; Kiałka M; Mrozińska S; Ociepka A; Krzysiek J
Przegl Lek; 2013; 70(2):81-4. PubMed ID: 23879009
[TBL] [Abstract][Full Text] [Related]
18. A novel insight into the anticancer mechanism of metformin in pancreatic neuroendocrine tumor cells.
Vitali E; Boemi I; Piccini S; Tarantola G; Smiroldo V; Lavezzi E; Brambilla T; Zerbi A; Carnaghi C; Mantovani G; Spada A; Lania AG
Mol Cell Endocrinol; 2020 Jun; 509():110803. PubMed ID: 32251713
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
20. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
